---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-24-000041"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:23:36.120965+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GeneDx Q2 revenue $68.9M (+52% YoY); raises FY24 revenue guidance to $255-265M

## Summary
- Exome/genome test revenue $50.7M (+77% YoY), volume 18,017 (+52% YoY).
- Adjusted gross margin from continuing ops 62% (up from 37% YoY).
- Adjusted net loss narrowed to $2.7M, an improvement of 93% YoY.
- GAAP net loss $29.2M including $13M one-time litigation charge.
- Raises FY2024 revenue guidance to $255-265M; reiterates path to profitability in 2025.

## SEC filing metadata
- accession: 0001818331-24-000041
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000041/0001818331-24-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833124000041/wgs-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-24-000041
- JSON: https://secwatch.observer/filing/0001818331-24-000041.json
- Plain text: https://secwatch.observer/filing/0001818331-24-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.